Stocks of pharmaceutical companies are seen trading range-bound with a negative bias next week following the Group of Ministers' proposal on the National Pharmaceutical Pricing Policy. The ministers' panel has finalised market-based weighted average prices for drug brands that enjoy more than 1% market share. The panel has included 348 drugs but has excluded combination drugs. According to the report, Indian companies that do not have a huge exposure to the domestic market would be insulated to some extent. The companies such as Dr. Reddy's Laboratories, Sun Pharmaceutical Industries, Lupin, Ranbaxy Laboratories and Cipla would be less impacted due to their presence in the exports space.
Pharma Stocks Outlook for the week: 01.10.2012-05.10.2012
Stocks of pharmaceutical companies are seen trading range-bound with a negative bias next week following the Group of Ministers' proposal on the National Pharmaceutical Pricing Policy. The ministers' panel has finalised market-based weighted average prices for drug brands that enjoy more than 1% market share. The panel has included 348 drugs but has excluded combination drugs. According to the report, Indian companies that do not have a huge exposure to the domestic market would be insulated to some extent. The companies such as Dr. Reddy's Laboratories, Sun Pharmaceutical Industries, Lupin, Ranbaxy Laboratories and Cipla would be less impacted due to their presence in the exports space.
